Delcath Systems, Inc.

DCTH • Medical - Devices

$16.48

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$655.27M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Crecimiento positivo de ingresos · 47.9%Flujo de caja libre positivo · 0.59Nivel de deuda manejable · 0.01Liquidez saludable · 10.92Múltiplo de ganancias caro · 134

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:26 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$16.48

Change0.00%

Shares Out39.76M

Market Cap$655.27M

Enterprise Value$561.83M

52W Range8.12 - 15.62

Beta0.49

P/E1,231.71

P/S6.87

P/B5.41

P/FCF36.83

EV/Sales5.89

Price$16.48

Change0.00%

Shares Out39.76M

Market Cap$655.27M

Enterprise Value$561.83M

52W Range8.12 - 15.62

Beta0.49

P/E1,231.71

P/S6.87

P/B5.41

P/FCF36.83

EV/Sales5.89

EV/EBITDA581.60

EV/FCF31.57

Earnings Yield0.08%

FCF Yield2.72%

Dividend Yield0.00%

Gross Margin86.16%

Oper. Margin0.77%

Profit Margin3.17%

Debt/Eq0.01

Current Ratio10.92

Quick Ratio9.98

Target$24.50

Target Upside48.67%

Target Median$24.50

Target Range17.00 - 32.00

Volume2.99M

Avg Volume467.44K

EPS Surprise0.06

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

40/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

53/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 47.9%Flujo de caja libre positivo · 0.59Nivel de deuda manejable · 0.01Liquidez saludable · 10.92Múltiplo de ganancias caro · 134

Analyst view

Analyst sentiment and price target

DCTH

Analyst sentiment

Based on 11 analyst votes · 2026-09-05

82/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$17.00

Promedio

$25.33

Mediana

$27.00

Alto

$32.00

Resumen de la compañía

IPO: 5/3/2018

Industria: Medical - Devices

P/B i: 5.41

Deuda / Patrimonio i: 0.01

Margen operativo: 0.77%

Margen neto: 3.17%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 10.92

Ratio rápido: 9.98

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Aharon Gil

Transacción: 05/13/2026

COMPRA

Cambio

+22,500

Precio

$11.61

Presentación

05/14/2026

Tipo

COMPRA

SALAMON STEVEN A J

Transacción: 05/13/2026

COMPRA

Cambio

+22,500

Precio

$11.61

Presentación

05/14/2026

Tipo

COMPRA

CZEREPAK ELIZABETH

Transacción: 05/13/2026

COMPRA

Cambio

+22,500

Precio

$11.61

Presentación

05/14/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Aharon Gil	COMPRA	+22,500	$11.61	05/13/2026	05/14/2026
SALAMON STEVEN A J	COMPRA	+22,500	$11.61	05/13/2026	05/14/2026
CZEREPAK ELIZABETH	COMPRA	+22,500	$11.61	05/13/2026	05/14/2026
Martell Bridget A	COMPRA	+22,500	$11.61	05/13/2026	05/14/2026
Sylvester John Richard	COMPRA	+22,500	$11.61	05/13/2026	05/14/2026
Pennell Sandra	COMPRA	+5,533	$9.04	03/06/2026	03/06/2026
MICHEL GERARD J	COMPRA	+11,200	$8.96	03/02/2026	03/03/2026
MICHEL GERARD J	COMPRA	+97,500	Not reported	02/17/2026	02/18/2026
MICHEL GERARD J	COMPRA	+195,000	$9.40	02/17/2026	02/18/2026
Rook Martha S.	COMPRA	+28,250	Not reported	02/17/2026	02/18/2026
Rook Martha S.	COMPRA	+56,500	$9.40	02/17/2026	02/18/2026
Vukovic Vojo	COMPRA	+28,250	Not reported	02/17/2026	02/18/2026
Vukovic Vojo	COMPRA	+56,500	$9.40	02/17/2026	02/18/2026
Pennell Sandra	COMPRA	+28,250	Not reported	02/17/2026	02/18/2026
Pennell Sandra	COMPRA	+56,500	$9.40	02/17/2026	02/18/2026
Muir Kevin	COMPRA	+28,250	Not reported	02/17/2026	02/18/2026
Muir Kevin	COMPRA	+56,500	$9.40	02/17/2026	02/18/2026
Hoffman David L.	COMPRA	+28,250	Not reported	02/17/2026	02/18/2026
Hoffman David L.	COMPRA	+56,500	$9.40	02/17/2026	02/18/2026
Sylvester John Richard	COMPRA	+4,386	$8.89	11/21/2025	11/25/2025

Sobre la compañía

Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

Fuente - Link

Competidores

AGL BWAY CERS MASS NAKA NPCE RXST SENS SMLR TCMD

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.

Zacks Investment Research

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:Wells Fargo Healthcare Conference on Thursday, September 10, 2026, in Boston, MAH.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 15, 2026, in New York, NYAbout Delcath Systems, Inc., HEPZATO KIT and CHEMO.

Business Wire

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Investment Research

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.094	-0.03	0.064
2026-02-26	-0.06299	-0.05	0.01299
2025-11-04	0.02	0.02	0
2025-08-06	0.026	0.07	0.044
2025-05-08	0.1	0.03	-0.07
2025-03-06	-0.1	0.05	0.15
2024-11-08	-0.13	-0.03	0.1
2024-08-05	-0.34	-0.48	-0.14
2024-05-14	-0.43	-0.43	0
2024-03-26	-0.67	-0.48	0.19
2023-11-13	-0.51	-0.61	-0.1
2023-08-09	-0.67	-0.58	0.09